Profile data is unavailable for this security.
About the company
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.
- Revenue in GBP (TTM)7.21m
- Net income in GBP-46.89m
- Incorporated2015
- Employees28.00
- LocationShield Therapeutics PLC3rd FlBaltic Business Quarters, Abbott's HillGATESHEAD NE8 3DUnited KingdomGBR
- Phone+44 19 1511 8500
- Websitehttps://www.shieldtherapeutics.com/
More ▼
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Genflow Biosciences PLC | 0.00 | -1.18m |
ImmuPharma PLC | 69.96k | -2.99m |
Cambridge Nutritional Sciences PLC | 9.05m | -3.21m |
Bivictrix Therapeutics PLC | 0.00 | -2.33m |
Proteome Sciences plc | 5.03m | -2.44m |
Chill Brands Group PLC | 146.62k | -3.64m |
Kanabo Group PLC | 895.00k | -7.99m |
Abingdon Health PLC | 5.34m | -2.24m |
Shield Therapeutics PLC | 7.21m | -46.89m |
Synairgen plc | 0.00 | -9.99m |
Incanthera PLC | 0.00 | -1.48m |
Genincode PLC | 1.72m | -6.73m |
Provexis plc | 598.08k | -496.59k |
Oncimmune Holdings PLC | 1.15m | -6.15m |
LungLife AI Inc | 36.67k | -4.32m |
Destiny Pharma PLC | 0.00 | -5.66m |
Data as of May 03 2024. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
FIL Investment Advisors (UK) Ltd.as of 18 May 2023 | 44.97m | 5.75% |
Jupiter Asset Management Ltd.as of 21 Jul 2023 | 34.13m | 4.36% |
Hargreaves Lansdown Asset Management Ltd.as of 05 May 2023 | 33.97m | 4.34% |
IG Markets Ltd.as of 08 Feb 2024 | 30.05m | 3.84% |
Premier Fund Managers Ltd.as of 05 May 2023 | 30.00m | 3.84% |
LGT Capital Partners AG (Investment Management)as of 08 Feb 2024 | 28.70m | 3.67% |
KW Investment Management Ltd.as of 08 Feb 2024 | 18.60m | 2.38% |
Maitland Asset Management (Pty) Ltd.as of 08 Feb 2024 | 11.09m | 1.42% |
Jarvis Investment Management Ltd.as of 08 Feb 2024 | 10.92m | 1.40% |
Killik & Co. LLPas of 05 May 2023 | 10.62m | 1.36% |
More ▼
Data from 30 Jun 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.